This document provides information about the Ontario HIV and Substance Use Training Program (OHSUTP). It summarizes the vision, mission, and mandate of OHSUTP, which is to provide training to substance use and mental health service providers to increase knowledge of HIV/AIDS and promote skills development. It also provides an overview of Fife House, the supportive housing organization that OHSUTP operates out of. Key information includes descriptions of Fife House's supportive housing programs and services for people living with HIV/AIDS.
Facing the Future of HIV and STD in Texas Epidemiology, Impact, and PrioritiesDSHS
This document summarizes epidemiological data on sexually transmitted diseases (STDs) and HIV in Texas. It finds that rates of STDs like chlamydia, gonorrhea, and syphilis are disproportionately high among Black populations. Nearly 25% of new HIV diagnoses in Texas are late diagnoses, defined as an AIDS diagnosis within a month of HIV diagnosis. The data shows the need for expanded testing, treatment, and prevention programs that address social and structural factors to curb the spread of STDs and HIV in communities.
HIV/AIDS in Special Population Groups in TexasDSHS
- The document discusses HIV trends among women in Texas based on demographic and surveillance data from 2000-2008. It finds that Hispanic women ages 25-34 in Dallas make up the largest proportion of new HIV cases. The primary risk factor for transmission differs by age and ethnicity, with intravenous drug use being most common among older non-Hispanic white women and heterosexual sex being most common among younger Hispanic women. Late testing remains a significant issue, with half of 2008 cases estimated to have been long term late testers. Further analysis is needed to understand socioeconomic barriers and cues to testing in order to reduce transmission rates.
This document summarizes national HIV prevention and care outcomes in the United States. Key metrics monitored include linkage to care after HIV diagnosis, retention in care, and viral suppression. Data on these indicators are collected through the National HIV Surveillance System and used to measure progress towards national goals. The document provides data on these indicators stratified by factors such as age, gender, race/ethnicity, and transmission category. It also discusses calculation methods and presents graphs illustrating trends in various indicators over time and across populations.
The Southern Nevada Health District identified a cluster of Hepatitis C cases linked to procedures at an endoscopy center in January 2008. This led to the largest disease notification operation in U.S. history as over 50,000 patients of the clinic were notified of their potential exposure. The health district conducted an investigation that included collecting questionnaires from exposed patients about their medical history and testing results. Over 7,000 questionnaires were processed and organized. The investigation identified two source cases of Hepatitis C transmission related to procedures at the clinics in July and September 2007. In total, 101 cases of Hepatitis C were classified as possibly associated with one of the clinics.
This document discusses stigma, discrimination, disclosure, and legal issues related to HIV. It begins by defining stigma and its impacts. It then discusses the roots of HIV stigma, including fear of contagion and negative assumptions about those infected. Multiple stigmas can compound issues for those living with HIV. Legal duties around disclosure are complex, with unclear guidelines around what constitutes significant risk of transmission. Non-disclosure can result in criminal charges but disclosure may not fully protect against prosecution. Community organizations have duties around confidentiality but not mandatory reporting.
Dr. Kathleen Brady (AACO)'s annual epidemiological update. This presentation was given to the Philadelphia EMA Ryan White Planning Council on Thursday, February 20, 2014.
This document provides information about the Ontario HIV and Substance Use Training Program (OHSUTP). It summarizes the vision, mission, and mandate of OHSUTP, which is to provide training to substance use and mental health service providers to increase knowledge of HIV/AIDS and promote skills development. It also provides an overview of Fife House, the supportive housing organization that OHSUTP operates out of. Key information includes descriptions of Fife House's supportive housing programs and services for people living with HIV/AIDS.
Facing the Future of HIV and STD in Texas Epidemiology, Impact, and PrioritiesDSHS
This document summarizes epidemiological data on sexually transmitted diseases (STDs) and HIV in Texas. It finds that rates of STDs like chlamydia, gonorrhea, and syphilis are disproportionately high among Black populations. Nearly 25% of new HIV diagnoses in Texas are late diagnoses, defined as an AIDS diagnosis within a month of HIV diagnosis. The data shows the need for expanded testing, treatment, and prevention programs that address social and structural factors to curb the spread of STDs and HIV in communities.
HIV/AIDS in Special Population Groups in TexasDSHS
- The document discusses HIV trends among women in Texas based on demographic and surveillance data from 2000-2008. It finds that Hispanic women ages 25-34 in Dallas make up the largest proportion of new HIV cases. The primary risk factor for transmission differs by age and ethnicity, with intravenous drug use being most common among older non-Hispanic white women and heterosexual sex being most common among younger Hispanic women. Late testing remains a significant issue, with half of 2008 cases estimated to have been long term late testers. Further analysis is needed to understand socioeconomic barriers and cues to testing in order to reduce transmission rates.
This document summarizes national HIV prevention and care outcomes in the United States. Key metrics monitored include linkage to care after HIV diagnosis, retention in care, and viral suppression. Data on these indicators are collected through the National HIV Surveillance System and used to measure progress towards national goals. The document provides data on these indicators stratified by factors such as age, gender, race/ethnicity, and transmission category. It also discusses calculation methods and presents graphs illustrating trends in various indicators over time and across populations.
The Southern Nevada Health District identified a cluster of Hepatitis C cases linked to procedures at an endoscopy center in January 2008. This led to the largest disease notification operation in U.S. history as over 50,000 patients of the clinic were notified of their potential exposure. The health district conducted an investigation that included collecting questionnaires from exposed patients about their medical history and testing results. Over 7,000 questionnaires were processed and organized. The investigation identified two source cases of Hepatitis C transmission related to procedures at the clinics in July and September 2007. In total, 101 cases of Hepatitis C were classified as possibly associated with one of the clinics.
This document discusses stigma, discrimination, disclosure, and legal issues related to HIV. It begins by defining stigma and its impacts. It then discusses the roots of HIV stigma, including fear of contagion and negative assumptions about those infected. Multiple stigmas can compound issues for those living with HIV. Legal duties around disclosure are complex, with unclear guidelines around what constitutes significant risk of transmission. Non-disclosure can result in criminal charges but disclosure may not fully protect against prosecution. Community organizations have duties around confidentiality but not mandatory reporting.
Dr. Kathleen Brady (AACO)'s annual epidemiological update. This presentation was given to the Philadelphia EMA Ryan White Planning Council on Thursday, February 20, 2014.
Evaluating HIV Clinical Care Quality in Massachusetts Sites Supported through...JSI
This presentation was produced by Jeanne Day, MPH; Nancy Reinhalter, RN; Joseph Musolino; Joseph Rego; Amy Flynn; Katelyn Flaherty Dore; Ashley Hatcher, as part of the HIV/AIDS Clinical Quality Assurance Project. For more information about the project, visit: http://www.jsi.com/JSIInternet/USHealth/project/display.cfm?ctid=na&cid=na&tid=40&id=21641
AIDSVu offers a variety of tools to help illustrate the impact of HIV in the United States.Visit www.AIDSVu.org for more map views and downloadable resources.
Integrating HIV Prevention with Hepatitis C Co‐Infection ProgramsCDC NPIN
This document discusses integrating hepatitis C screening and prevention programs into existing HIV/AIDS and other health services. It provides an overview of hepatitis C and its prevalence among people living with HIV. Integrating hepatitis C services can meet more client needs, reduce barriers, and leverage existing infrastructure. Modules cover hepatitis basics, risk assessment, harm reduction, and strategies for different settings like HIV/AIDS programs, LGBT organizations, and corrections. Lessons learned indicate developing HIV/hepatitis co-infection curricula and integrating hepatitis services can better meet client needs. Next steps include creating more inclusive HIV programs and training non-medical providers.
Theodoros F. Katsivas, M.D., M.A.S., of UC San Diego Owen Clinic, presents "San Diego Primary Care Providers' Attitudes to HIV and HIV Testing" at AIDS Clinical Rounds
The document discusses health care options and services available to veterans through programs like the VA health care system, TRICARE, and CHAMPVA. It provides details on eligibility requirements, covered benefits like inpatient and outpatient care, preventative services, and pharmacy. Statistics are presented on where veterans receive care, with most having Medicare or other private insurance. The VA performs well on quality measures compared to non-VA standards and most of its utilization is for outpatient services.
Was your Sex Ed lacking? Find the missing chapter with iPROVIBE.com. "Let the Vibe be with you." -proVibe Promoting Self-Love - Sex Ed - Dating Prerequisites - Wellness http://iprovibe.com/ http://gplus.to/iprovibe http://www.facebook.com/iprovibe https://twitter.com/iproVibe http://pinterest.com/iprovibe/
Cameroon has a HIV prevalence rate of 4.3% nationally, ranging from 1.2-7.2% by region. Women have a higher prevalence of 5.6% compared to 2.9% for men. Challenges include stigma and discrimination faced by 70% of PLWHA, stockouts leading to only 33% of eligible adults and 34% of children accessing ARVs, and underfunding with only 55% of needed resources mobilized from 2011-2013. Priority interventions include behavior change communication, condom usage, voluntary counseling and testing, PMTCT, STDs, and expanding access to ARVs. Some progress has been made with increased condom distribution, 57% coverage of PMTCT among
This document discusses various legal and ethical issues related to HIV/AIDS, including:
1. The linkages between human rights and HIV/AIDS, noting that human rights protections are important for reducing stigma and empowering at-risk groups.
2. Issues around HIV testing, confidentiality, and the roles of criminal law, highlighting the importance of voluntary testing and informed consent.
3. Ethical considerations regarding biomedical research on HIV/AIDS and the need to balance research advancement with human subject protections.
4. Special circumstances that raise complex issues, such as providing care to victims of rape or reducing mother-to-child transmission through antiretroviral treatment.
The document discusses hepatitis C, including what it is, how it is transmitted, testing and treatment options. It notes that hepatitis C is caused by a virus and is transmitted through blood-to-blood contact, often from sharing drug injection equipment. Testing can determine if one has been exposed through antibody tests or detect current infection. While some may clear the infection, others may develop liver damage or other complications over many years without treatment. Treatment options including interferon are discussed, as well as lifestyle changes to prevent further liver damage.
This document describes a proposed community-based participatory research program to decrease HIV and its risk factors among African Americans in Washington D.C. The program will provide HIV/AIDS education to participants aged 13-30 across 8 African American churches over 8 weekly classes. Data will be collected pre- and post-intervention to measure changes in risk behaviors like condom use and number of sexual partners. Collaboration with local health and community organizations is also discussed. The goal is to address common risk factors like access to healthcare and housing through faith-based education and prevention strategies.
This study analyzed data from 2009 on newly reported HIV cases and their sexual partners in Dallas County, Texas. Of the 530 sexual partners tested who were contacts of people newly diagnosed with HIV, 74.7% (396 people) were previously aware of their positive HIV status, while 25.3% (134 people) were newly diagnosed. Although contact investigations are still effective, the majority of contacts for people newly diagnosed were already aware of their HIV positive status. Increasing HIV testing and early diagnosis can help lower transmission rates by decreasing the number of unaware infections.
Kathleen Brady of the PDPH presented the annual report on the HIV epidemic in Philadelphia at the February 2017 meeting of the Philadelphia Ryan White Part A Planning Council.
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
This workshop is designed to talk about the impact of STDs on youth under the age of 25. This workshop will discuss the importance of sexual health screenings, partner management, and current data around STD morbidity rates. We will also talk about current STD clinical recommendations for the treatment of gonorrhea, chlamydia, and syphilis. Participants will engage in an interactive activity where they will sharpen their skills on effective partner management strategies.
This document discusses empowering youth regarding HIV/AIDS through open communication and education. It notes that over 50% of HIV-positive youth do not know their status. School and health officials want to better engage youth through respectful dialogue to provide information to help change behaviors and potentially save lives. While uncomfortable, adults and youth must learn to listen to each other on this important topic.
The document presents a progress report from the Fulton County Task Force on HIV/AIDS on developing a strategy to end AIDS in the county. It outlines goals to reduce new infections, increase access to care and health outcomes, reduce disparities, and coordinate the local response. Data shows high rates of HIV among Black residents and rising diagnoses among Black gay and bisexual men. Objectives are presented to increase HIV testing, linkage to and retention in care, viral suppression, housing support, and addressing social determinants. The strategy aims to eliminate perinatal transmission and decrease new diagnoses by at least 25% by 2020.
Kathleen Brady from the Philadelphia Department of Public Health presented her annual updated on the HIV Epidemic in Philadelphia at a February 2015 combined meeting of the Philadelphia Ryan White Part A Planning Council and the HIV Prevention Planning Group.
The document summarizes HIV engagement in care data for Philadelphia and nationally. It finds that in Philadelphia in 2009, 82% of people living with HIV were aware of their infection, 62% were linked to care, 52% were retained in care, 46% were prescribed antiretroviral therapy (ART), and 30% had viral suppression. Nationally, the rates were slightly higher. The epidemic in Philadelphia primarily affects minorities and transmission is mostly through men who have sex with men and heterosexual contact. While new AIDS cases have declined 25%, growing numbers are living with HIV. Around 20-30% have unmet needs and are not engaged in regular HIV care.
Evaluating HIV Clinical Care Quality in Massachusetts Sites Supported through...JSI
This presentation was produced by Jeanne Day, MPH; Nancy Reinhalter, RN; Joseph Musolino; Joseph Rego; Amy Flynn; Katelyn Flaherty Dore; Ashley Hatcher, as part of the HIV/AIDS Clinical Quality Assurance Project. For more information about the project, visit: http://www.jsi.com/JSIInternet/USHealth/project/display.cfm?ctid=na&cid=na&tid=40&id=21641
AIDSVu offers a variety of tools to help illustrate the impact of HIV in the United States.Visit www.AIDSVu.org for more map views and downloadable resources.
Integrating HIV Prevention with Hepatitis C Co‐Infection ProgramsCDC NPIN
This document discusses integrating hepatitis C screening and prevention programs into existing HIV/AIDS and other health services. It provides an overview of hepatitis C and its prevalence among people living with HIV. Integrating hepatitis C services can meet more client needs, reduce barriers, and leverage existing infrastructure. Modules cover hepatitis basics, risk assessment, harm reduction, and strategies for different settings like HIV/AIDS programs, LGBT organizations, and corrections. Lessons learned indicate developing HIV/hepatitis co-infection curricula and integrating hepatitis services can better meet client needs. Next steps include creating more inclusive HIV programs and training non-medical providers.
Theodoros F. Katsivas, M.D., M.A.S., of UC San Diego Owen Clinic, presents "San Diego Primary Care Providers' Attitudes to HIV and HIV Testing" at AIDS Clinical Rounds
The document discusses health care options and services available to veterans through programs like the VA health care system, TRICARE, and CHAMPVA. It provides details on eligibility requirements, covered benefits like inpatient and outpatient care, preventative services, and pharmacy. Statistics are presented on where veterans receive care, with most having Medicare or other private insurance. The VA performs well on quality measures compared to non-VA standards and most of its utilization is for outpatient services.
Was your Sex Ed lacking? Find the missing chapter with iPROVIBE.com. "Let the Vibe be with you." -proVibe Promoting Self-Love - Sex Ed - Dating Prerequisites - Wellness http://iprovibe.com/ http://gplus.to/iprovibe http://www.facebook.com/iprovibe https://twitter.com/iproVibe http://pinterest.com/iprovibe/
Cameroon has a HIV prevalence rate of 4.3% nationally, ranging from 1.2-7.2% by region. Women have a higher prevalence of 5.6% compared to 2.9% for men. Challenges include stigma and discrimination faced by 70% of PLWHA, stockouts leading to only 33% of eligible adults and 34% of children accessing ARVs, and underfunding with only 55% of needed resources mobilized from 2011-2013. Priority interventions include behavior change communication, condom usage, voluntary counseling and testing, PMTCT, STDs, and expanding access to ARVs. Some progress has been made with increased condom distribution, 57% coverage of PMTCT among
This document discusses various legal and ethical issues related to HIV/AIDS, including:
1. The linkages between human rights and HIV/AIDS, noting that human rights protections are important for reducing stigma and empowering at-risk groups.
2. Issues around HIV testing, confidentiality, and the roles of criminal law, highlighting the importance of voluntary testing and informed consent.
3. Ethical considerations regarding biomedical research on HIV/AIDS and the need to balance research advancement with human subject protections.
4. Special circumstances that raise complex issues, such as providing care to victims of rape or reducing mother-to-child transmission through antiretroviral treatment.
The document discusses hepatitis C, including what it is, how it is transmitted, testing and treatment options. It notes that hepatitis C is caused by a virus and is transmitted through blood-to-blood contact, often from sharing drug injection equipment. Testing can determine if one has been exposed through antibody tests or detect current infection. While some may clear the infection, others may develop liver damage or other complications over many years without treatment. Treatment options including interferon are discussed, as well as lifestyle changes to prevent further liver damage.
This document describes a proposed community-based participatory research program to decrease HIV and its risk factors among African Americans in Washington D.C. The program will provide HIV/AIDS education to participants aged 13-30 across 8 African American churches over 8 weekly classes. Data will be collected pre- and post-intervention to measure changes in risk behaviors like condom use and number of sexual partners. Collaboration with local health and community organizations is also discussed. The goal is to address common risk factors like access to healthcare and housing through faith-based education and prevention strategies.
This study analyzed data from 2009 on newly reported HIV cases and their sexual partners in Dallas County, Texas. Of the 530 sexual partners tested who were contacts of people newly diagnosed with HIV, 74.7% (396 people) were previously aware of their positive HIV status, while 25.3% (134 people) were newly diagnosed. Although contact investigations are still effective, the majority of contacts for people newly diagnosed were already aware of their HIV positive status. Increasing HIV testing and early diagnosis can help lower transmission rates by decreasing the number of unaware infections.
Kathleen Brady of the PDPH presented the annual report on the HIV epidemic in Philadelphia at the February 2017 meeting of the Philadelphia Ryan White Part A Planning Council.
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
This workshop is designed to talk about the impact of STDs on youth under the age of 25. This workshop will discuss the importance of sexual health screenings, partner management, and current data around STD morbidity rates. We will also talk about current STD clinical recommendations for the treatment of gonorrhea, chlamydia, and syphilis. Participants will engage in an interactive activity where they will sharpen their skills on effective partner management strategies.
This document discusses empowering youth regarding HIV/AIDS through open communication and education. It notes that over 50% of HIV-positive youth do not know their status. School and health officials want to better engage youth through respectful dialogue to provide information to help change behaviors and potentially save lives. While uncomfortable, adults and youth must learn to listen to each other on this important topic.
The document presents a progress report from the Fulton County Task Force on HIV/AIDS on developing a strategy to end AIDS in the county. It outlines goals to reduce new infections, increase access to care and health outcomes, reduce disparities, and coordinate the local response. Data shows high rates of HIV among Black residents and rising diagnoses among Black gay and bisexual men. Objectives are presented to increase HIV testing, linkage to and retention in care, viral suppression, housing support, and addressing social determinants. The strategy aims to eliminate perinatal transmission and decrease new diagnoses by at least 25% by 2020.
Kathleen Brady from the Philadelphia Department of Public Health presented her annual updated on the HIV Epidemic in Philadelphia at a February 2015 combined meeting of the Philadelphia Ryan White Part A Planning Council and the HIV Prevention Planning Group.
The document summarizes HIV engagement in care data for Philadelphia and nationally. It finds that in Philadelphia in 2009, 82% of people living with HIV were aware of their infection, 62% were linked to care, 52% were retained in care, 46% were prescribed antiretroviral therapy (ART), and 30% had viral suppression. Nationally, the rates were slightly higher. The epidemic in Philadelphia primarily affects minorities and transmission is mostly through men who have sex with men and heterosexual contact. While new AIDS cases have declined 25%, growing numbers are living with HIV. Around 20-30% have unmet needs and are not engaged in regular HIV care.
The document summarizes HIV care continuum and engagement in care data for Philadelphia. Key points:
- In 2010, 82% of those diagnosed with HIV in Philadelphia were linked to care, 54% remained in care, 49% were on antiretroviral therapy (ART), and 38% had suppressed viral loads.
- Engagement in care varies by demographic group - males, blacks, Latinos, MSM, and younger age groups have lower rates of retention, ART use, and viral suppression compared to females, whites, heterosexuals, and older adults.
- 18% of those living with HIV/AIDS in the Philadelphia area had unmet needs for primary medical care in 2012, with higher
Read the article on the following 2 pages, Fighting HIV a Commu.docxcatheryncouper
Read the article on the following 2 pages, “Fighting HIV a Community at a Time.” , answer the following questions. Please type your answers…complete and thoughtful responses…1/2 page, single spaced minimum.
1. Statistically as many as 20-25% of people who are HIV positive do not know they are infected. Why do people not get tested if they engage in risky behaviors (unprotected sex and/or IV drug use with used needles)? Give reasons and rationales for their decision not to get tested.
2. In 2006 only about half of Washington D.C. residents who were tested positive for HIV saw a doctor about it within 6 months. They are contagious during that time. Again, why would someone who receives a positive diagnosis, not get treatment? Is a diagnosis of HIV different from other STDs? Why or why not?
3. The “test and treat” program in D.C. and the Bronx improved the follow-up of prompt medical care. What are the statistics?
4. At the end of the article, it states the profile of who is most resistant to being tested and treated. What is it about that particular group of people that would make them resistant?
Fighting HIV a Community at a Time Susan Okie, New York Times, Oct. 27, 2009
WASHINGTON- Federal health officials are preparing a plan to study a bold new strategy to stop the spread of the AIDS virus: routinely testing virtually every adult in a community, and promptly treating those found to be infected. The strategy is called “test and treat,” and officials say the two sites for the three-year study will be the District of Columbia and the Bronx--locales with some of the nation’s highest rates of infection with HIV.
The officials emphasize that this is just a first step. The goal is not to measure whether “test and treat” actually works to slow and epidemic, but whether such a strategy can even be carried out, given the many barriers to being tested and getting medical care.
On the path from infection to treatment, “we lose people at every single step,” said Dr. Shannon L. Hader, director of the HIV/AIDS administration at this city’s Department of Health.
As many as 5 percent of the adults in the District of Columbia are infected--a rate Dr. Hader says is comparable with those in West Africa--and one-third to one-half do not even know they harbor the virus. (Nationwide, 20 percent to 25 percent of people who are HIV positive do not know of their infections, according to the federal Centers for Disease Control and Prevention.)
And even when infection is diagnosed, “getting people from the field to the doctor is the hardest component,” said Angela Fulwood Wood, deputy director of Family and Medical Counseling Service, and agency that operates a mobile HIV testing clinic here. Often, she added, someone who has just tested positive “can walk off that day and decide, ‘I’m going to pretend that never happened.’ In 2006, only about half of D.C. reside ...
AIDS Legal & Ethical Implications HIV.pptxaiabkkau
This document discusses HIV and AIDS, including routes of HIV transmission, definitions of key terms, legal and ethical implications, and guidelines regarding testing and treatment. It covers topics such as confidentiality, informed consent, disclosure to partners/healthcare workers, discrimination protections, and duties of healthcare providers. The key points are that individuals with HIV/AIDS have rights to privacy, non-discriminatory treatment and care, and protections against unwanted disclosure of their status. Healthcare providers have ethical duties to provide care without judgment and maintain confidentiality, while also protecting others from foreseeable risks of transmission.
Dr. Kathleen Brady of Philadelphia's AIDS Activities Coordinating Office (AACO) gave this presentation at the January 9, 2013 Comprehensive Planning Committee meeting.
This document provides an overview of HIV/AIDS including:
1. It describes what HIV and AIDS are, how HIV causes AIDS, and their differences.
2. The main ways HIV can be transmitted and the body fluids involved in transmission are outlined.
3. Details about HIV testing procedures and window periods are explained.
4. Michigan laws regarding HIV/AIDS disclosure and prenatal testing are summarized.
5. Statistics on HIV/AIDS prevalence locally and nationally are presented.
The UC San Diego AntiViral Research Center sponsors weekly presentations on infectious diseases research and clinical practices. A presentation on whether widespread HIV treatment can end transmission discussed recent trends showing HIV declining among adolescents and young adults in the US. The presentation reviewed research showing that early HIV treatment dramatically reduces heterosexual transmission but some transmission may still occur through anal sex among men who have sex with men on antiretroviral therapy. Future interventions could focus on optimizing HIV treatment, comparing antiretroviral regimens, and suppressing coinfections like CMV to further reduce HIV transmission.
This document summarizes HIV and STI surveillance data from the Chicago Department of Public Health. Some key points:
- In 2015, there were 921 new HIV diagnoses in Chicago and 23,355 people living with HIV. Non-Hispanic Blacks had the highest rates of new diagnoses.
- Rates of chlamydia, gonorrhea, and syphilis were also highest among Non-Hispanic Blacks.
- The report shows progress in HIV care with 79% linked to care within 1 month of diagnosis, but also highlights ongoing health inequities faced by certain groups.
- Data are used to guide CDPH's efforts in preventing transmission and increasing access to treatment.
This webinar discussed how to educate Nurse Practitioners who have completed Community Health Center. Inc’s NP Residency or NPs who have significant experience as a Primary Care Provider on the integration of specialty care for key populations, including:
• HIV care
• Hepatitis C management
• Medication-assisted treatment for opioid use and other substance use disorders
• Sexually transmitted disease (STI) screening and management
• Lesbian, Gay, Bisexual, Transgender, Questioning, Intersex, Asexual (LGBTQIA+) health, including hormone replacement therapy and gender affirming care.
Panelists:
• Charise Corsino, MA, Program Director, Nurse Practitioner Residency Programs, Community Health Center, Inc.
• Marwan Haddad, MD, MPH, AAHIVS, Medical Director, Center for Key Populations, Community Health Center, Inc.
• Jeannie McIntosh, APRN, FNP-C, AAHIVS, Family Nurse Practitioner, Center for Key Populations, Community Health Center, Inc.
Similar to HIV: NEW PUBLIC HEALTH INTERVENTIONS (20)
Katherine Promer Flores, MD (she/her)
Staff Physician
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California San Diego
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
Maile Young Karris, MD
Associate Professor
Co-Director San Diego Center for AIDS Research Clinical Investigations Core
Divisions of Infectious Diseases & Global Public Health and Geriatrics & Gerontology
Department of Medicine
University of California San Diego
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Jocelyn Keehner, MD
Infectious Disease Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
This presentation summarizes research on cryptococcal antigen screening and treatment in resource-limited settings. It finds that screening individuals with CD4 counts <100 cells/uL and <200 cells/uL can reduce mortality, and point-of-care tests now enable screening in primary care clinics. Studies of simplified treatment regimens show promise, such as using high-dose liposomal amphotericin B for only 1-2 weeks. Field work in Mozambique demonstrated a 7.3% prevalence of cryptococcal antigenemia through screening at two clinics, and identified opportunities to improve care through expanded screening and ambulatory treatment models.
Richard Garfein, PhD, MPH
Professor
Herbert Wertheim School of Public Health and Human Longevity Science
Adjunct Professor
Division of Infectious Disease and Global Public Health
Department of Medicine
University of California, San Diego
Este documento fornece informações sobre uma sessão de treinamento virtual sobre HIV/AIDS para militares internacionais. A agenda inclui atualizações sobre a vacina COVID-19 e sua implementação na Nigéria, com discussões sobre implicações para pessoas vivendo com HIV. A sessão é conduzida pelo programa MIHTP-ECHO com o objetivo de melhorar o atendimento e prevenção de HIV em militares em todo o mundo.
This document provides information about a MIHTP-ECHO training session on COVID-19 vaccines. It includes the agenda, presenters, and an overview of MIHTP and the ECHO model. The presentation by Dr. Allen McCutchan will discuss COVID epidemiology, vaccine mechanisms of action, effectiveness, safety, and duration of protection. It will also cover implications for people living with HIV and emerging variants. A presentation by Captain UO Adekanye will provide an update on Nigeria's COVID vaccine rollout and implications for people living with HIV. The session aims to inform participants and facilitate discussion on these topics.
Laura Bamford, MD, MSCE
Associate Professor of Medicine
Medical Director, Owen Clinic
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Davey Smith, MD, MAS
Professor of Medicine
Chief, Division of Infectious Diseases and Global Public Health
Co-Director, San Diego Center for AIDS Research (CFAR)
Department of Medicine
University of California, San Diego
Elliot Welford, MD
Infectious Diseases Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Darcy Wooten, MD
Assistant Professor of Medicine
Associate Program Director, Infectious Diseases Fellowship
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
This document summarizes a presentation on new and investigational antiretrovirals given at the UC San Diego HIV & Global Health Rounds. The presentation reviewed fostemsavir, cabotegravir/rilpivirine, leronlimab, islatravir, and lenacapavir. For each drug, the presenter discussed indications, dosing, efficacy and safety data from clinical trials, resistance profiles, and potential advantages and limitations. The goal of the HIV & Global Health Rounds is to provide clinicians and researchers with the most up-to-date information on HIV, hepatitis, tuberculosis, and other infectious diseases.
This document summarizes a presentation on hepatitis C virus (HCV) epidemiology and screening recommendations. It discusses global and local HCV prevalence, the health impacts and economic costs of HCV infection, and the potential for HCV elimination with new direct-acting antiviral treatments. It also reviews evolving HCV screening guidelines and epidemiologic trends in the US, including increasing infections associated with opioid epidemics. Risk factors for HCV transmission are identified based on a study of HCV-positive blood donors.
Winston Tilghman, MD
Medical Director, STD Controller
HIV, STD & Hepatitis Branch of Public Health Services
County of San Diego Health & Human Services Agency
More from UC San Diego AntiViral Research Center (20)
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
2. HIV: NEW PUBLIC HEALTH
INTERVENTIONS
Patrick Loose & Heidi Aiem
HIV, STD & Hepatitis Branch
Public Health Services
County of San Diego Health & Human Services Agency
4. NATIONAL HIV/AIDS STRATEGY
The United States will become a
place where new HIV infections are
rare and when they do occur, every
person regardless of age, gender,
race/ethnicity, sexual orientation,
gender identity or socio-economic
circumstance, will have unfettered
access to high quality, life-
extending care, free from stigma
and discrimination.
5. HIV IN SAN DIEGO COUNTY
Demographic Group
2014- PREVALENCE
AS OF 12/31/14
Race/Ethnicity HIV AIDS
# % # %
White, not Hispanic 6,623 52.1 3,727 49.6
Black, not Hispanic 1,793 14.1 1,142 15.2
Hispanic 3,674 28.9 2,330 31.0
Asian/Pacific Islander 420 3.3 218 2.9
American Indian/Alaska Native 89 0.7 38 0.5
Multi-Race 114 0.9 60 0.8
Total 12,713 100 7,515 100
8. CASCADE OF CARE
100%
43%
51%
100%
57%
67%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Total living with HIVa Retention in careb Viral suppressionc
Percent
Persons living with HIV, diagnosed as a resident or known to have
moved to San Diego (N=16,898)
Persons living with HIV, recently diagnosed or recently in care in San
Diego (N=12,863)
Total living with HIVa Virally suppressedcHad > 2 lab testsb
aPersons living with HIV, diagnosed as a resident of San Diego or known to have moved to San Diego defined as persons diagnosed with HIV through
12/31/2013 and living through 12/31/2014, regardless of stage of disease. Recently diagnosed or recently in care in San Diego defined as persons
diagnosed with HIV 2009-2013 or diagnosed prior to 2009 and having at least one CD4 or viral load between 2010 and 2014, living through 12/31/2014,
regardless of stage of disease.
bOf the total, persons who had >2 CD4 or viral load tests at least 3 months apart during 2014.
cOf the total, persons wih virologic supression (<200 copies/mL) at most recent test during 2014.
HIV Care Continuum, San Diego County, 2014
9. 36%
43%43%
49%
45% 46%
38%
44%
34%
28%27%* 28%*
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1 2
Percent
MSM Continuum of HIV Care by Race/ethnicity
San Diego County, FY 2012/2013
Overall Asian/PI Hispanic White American Indian Black
*Statistically lower than the overall percent; p<.05.
aSan Diego data source: FY 12/13 unmet need file. Of those diagnosed with HIV disease, persons who had >=2 CD4 or viral load tests at least 3 months apart during FY
12/13.
bSan Diego data source: Of those diagnosed with HIV disease, persons with virologic suppression (<=200 copies/mL) at most recent test during FY 12/13.
Viral suppressionbRetention in carea
CONTINUUM OF CARE BY
RACE/ETHNICITY
14. LEG AUTHORITY
LHO AUTHORITY TO USE HIV SURVEILLANCE DATA
FOR PARTNER SERVICES
California Health and Safety Code (HSC) Section 120175 provides LHOs with broad
authority to proactively investigate cases of disease, to ascertain the infection source, and
take measures as may be necessary to prevent the spread of the disease or occurrence of
additional cases. Thus, LHOs or their designees, who may be STD Control Branch staff or
DIS/partner services staff working on the LHO’s behalf, may use HIV surveillance data to
identify HIV-infected individuals and initiate partner services with them. HIV surveillance
data consists of LHD-acquired/developed data or data shared with the LHO by the state or
another jurisdictional LHO. LHOs and their DIS/partner services staff should ensure that
their activities adhere to CDC security and confidentiality requirements and California HSC
confidentiality protections within both the surveillance and partner services areas before
proceeding with utilizing HIV surveillance data to identify potential clients for partner
services.
15. LOCAL HEALTH OFFICERS OR THEIR DESIGNEES,
INCLUDING PARTNER SERVICES STAFF, MAY:
Tell anyone reasonably believed to be a spouse, or sex, or needle-sharing partner of
a person who has tested positive for HIV about their exposure to HIV. The LHO or
their designees may not disclose any identifying information about the person with
HIV or the physician making the report to the LHD. Any person to whom the
disclosure is made must be referred for appropriate care and follow-up. Health and
Safety Code (HSC) Section 121015[d)])
16. STATE/LOCAL HEALTH DEPARTMENT HIV
SURVEILLANCE STAFF MAY:
Disclose personally identifying information about HIV-positive reported individuals to
other local and state health department staff without written authorization. HSC
Section 121025(b) specifically authorizes state and local public health agencies to
disclose personally identifying information to CDPH and to other local public health
agencies when the information is necessary for the investigation, control, or
surveillance of disease. This includes partner services. (HSC Section 121015[d)])
17. PHYSICIANS OR SURGEONS MAY:
With the written consent of the patient with HIV, provide LHO or the LHD partner
services staff the patient’s contact information for partner services. (HSC Section
121015[a)])
Without the written consent of the patient with HIV, notify the spouse, or sex, or
needle-sharing partners of the patient if the physician or surgeon: 1) discusses the
test results with the patient; 2) offers the patient appropriate educational and
psychological counseling, including information on the risks of transmitting HIV to
other people and methods of avoiding those risks; 3) attempts to obtain the patient’s
voluntary consent for notification of their contacts; and 4) notifies the patient of their
intent to notify the patient’s contacts prior to any notification. (HSC Section
121015[b)])
18. HIV & STD REPORTING
STD REPORTING
STD Surveillance Unit
619-692-8501
HIV REPORTING
HIV/AIDS Epidemiology Unit
619-692-8545